Other studies found that cancer cells were FOXP3 positive in 57% of HER2+ breast tumors [30] and in 66% of archival samples from human breast cancer patients [10], indicating that our sample of TNBC demonstrated a high expression of this protein and that FOXP3 may have different expression levels in subtypes of breast cancer, with specific prognostic implications. This evidence concerns the gene ERBB2 and breast neoplasm.